Browse > Article

Shigellosis  

Niyogi Swapan Kumar (National Institute of Cholera and Enteric Diseases P-33)
Publication Information
Journal of Microbiology / v.43, no.2, 2005 , pp. 133-143 More about this Journal
Abstract
Shigellosis is a global human health problem. Four species of Shigella i.e. S. dysenteriae, S. flexneri, S. boydii and S. sonnei are able to cause the disease. These species are subdivided into serotypes on the basis of O-specific polysaccharide of the LPS. Shigella dysenteriae type 1 produces severe disease and may be associated with life-threatening complications. The symptoms of shigellosis include diarrhoea and/or dysentery with frequent mucoid bloody stools, abdominal cramps and tenesmus. Shigella spp. cause dysentery by invading the colonic mucosa. Shigella bacteria multiply within colonic epithelial cells, cause cell death and spread laterally to infect and kill adjacent epithelial cells, causing mucosal ulceration, inflammation and bleeding. Transmission usually occurs via contaminated food and water or through person-to-person contact. Laboratory diagnosis is made by culturing the stool samples using selective/differential agar media. Shigella spp. are highly fragile organism and considerable care must be exercised in collecting faecal specimens, transporting them to the laboratories and in using appropriate media for isolation. Antimicrobial agents are the mainstay of therapy of all cases of shigellosis. Due to the global emergence of drug resistance, the choice of antimicrobial agents for treating shigellosis is limited. Although single dose of norfloxacin and ciprofloxacin has been shown to be effective, they are currently less effective against S. dysenteriae type 1 infection. Newer quinolones, cephalosporin derivatives, and azithromycin are the drug of choice. However, fluoroquinolone-resistant S. dysenteriae type 1 infection have been reported. Currently, no vaccines against Shigella infection exist. Both live and subunit parenteral vaccine candidates are under development. Because immunity to Shigella is serotype-specific, the priority is to develop vaccine against S. dysenteriae type 1 and S. flexneri type 2a. Shigella species are important pathogens responsible for diarrhoeal diseases and dysentery occurring all over the world. The morbidity and mortality due to shigellosis are especially high among children in developing countries. A recent review of literature (KotIoff et al.,1999) concluded that, of the estimated 165 million cases of Shigella diarrhoea that occur annually, $99\%$ occur in developing countries, and in developing countries $69\%$ of episodes occur in children under five years of age. Moreover, of the ca.1.1 million deaths attributed to Shigella infections in developing countries, $60\%$ of deaths occur in the under-five age group. Travellers from developed to developing regions and soldiers serving under field conditions are also at an increased risk to develop shigellosis.
Keywords
Citations & Related Records

Times Cited By Web Of Science : 137  (Related Records In Web of Science)
Times Cited By SCOPUS : 116
연도 인용수 순위
1 Ashkenazi, S., G Dinari, A. Zevulunov, and M. Nitzan, 1987. Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children. Am. J. Dis. Child. 141, 208-210   PUBMED
2 Ashkenazi, S., J.H. Passwell, E. Harlev, D. Miron, R. Dagan, N. Farzan, R. Ramon, E. Majady, D.A. Bryla, A.B. Karpas, J.B. Robbins, and R. Schneerson. The Israel Paediatric Shigella Study Group. 1999. Safety and immunogenecity of Shigella sonnei and Shigella flexneri 2a O specific polysaccharide conjugates in children. J. Infect. Dis. 179, 1565-1568   DOI   ScienceOn
3 Bennish, M.L., M.A. Salam, R. Haider, and M. Barza 1990. Therapy for Shigellosis. II. Randomized,double-blind comparison of ciprofloxacin and ampicillin. J. Infect. Dis. 162, 711-716   DOI   PUBMED   ScienceOn
4 Bennish, M.L. 1991. Potentially lethal complications of shigellosis. Rev. Infect. Dis. 13(Suppl. 4), S319-324   DOI
5 Berlutti, E, M. Casalino, C. Zagaglia, P.A. Frandiani, P. Visca, and M. Nicoletti. 1998. Expression of the virulence plasmid-carried apyrase gene (apy) of enteroinvasive Escherichia coli and Shigella flexneri is under the control of H-NS and the VirF and VirB regulatory cascade. Infect. Immun. 66, 4957-4964   PUBMED
6 Bhattacharya, M.K., G.B. Nair, D. Sen, M. Paul, A. Debnath, A. Nag, D. Dutta, P. Dutta, S.C. Pal, and S.K. Bhattacharya. 1992. Efficacy of norfloxacin for shigellosis: A double-blind randomized clinical trial. J. Diarrhoeal. Dis. Res. 10, 146-150   PUBMED
7 Bhattacharya, S.K., P. Dutta, D. Dutta, M.K. Bhattacharya, D. Sen, M.R. Saha, G.B. Nair, P. Das, S.N. Sikdar, R. Bose, and S.C. Pal. 1987. Relative efficacy of trimethoprim-sulfamethoxazole and nalidixic acid for acute invasive diarrhoea. Antimicrob. Agent Chemother. 31,837
8 Black, R.E., K.H. Brown, S. Becker, A.R. Alim, and I. Huq. 1982. Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. II. Incidence of diarrhoea and association with known pathogen. Am. J. Epidemiol. 115,315-324   PUBMED
9 Chakrabarti, M.K., J. Bhattacharya, M.K. Bhattacharya, G.B. Nair, S.K. Bhattacharya, and D. Mahalanabis. 1999. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr. 88, 161-165   DOI   ScienceOn
10 Cohen, D., S. Ashkenazi, M.S. Green, M. Gdalevich, G. Robin, R. Slepon, M. Yavzori, N. Orr, C. Block, I. Ashkenazi, J. Shemer, D.N. Taylor, T.L. Hale, J.C. Sadoff, D. Pavliakova, R. Schneerson, and J.B. Robbins. 1997. Double-blind vaccine-controlled randomized efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet. 349, 155-159   DOI   ScienceOn
11 Du Pont, H.L., M.M. Levine, R.B. Hornick, and S.B Formal. 1989. Inoculum size in shigellosis and implications for expected mode of transmission J. Infect. Dis. 159, 1126-1128   DOI   PUBMED   ScienceOn
12 Fontaine, A, J. Arondel, and P.J. Sansonetti. 1988. Role of Shiga toxin in the pathogenesis of bacillary dysentery studied using a tox mutant of Shigella dysenteriae type 1. Infect. Immun. 56, 3099-3109   PUBMED
13 Gangarosa, E.J., D.R. Perera, L.J. Mata, C.M. Morris, G Guzman, and L.B. Reller. 1970. Epidemic Shiga bacillus dysentery in Central America. II. Epidemiologic studies in 1969. J. Infect. Dis. 122, 181-190   DOI   PUBMED   ScienceOn
14 Gendrel, D. and F. Moulin. 2001. Fluoroquinolones in paediatrics. Paediatr. Drugs. 3(5), 365-377   DOI   ScienceOn
15 Hartman, A.B. and M.M. Venkatesan. 1998. Construction of a stable attenuated Shigella sonnei Delta virG vaccine strain, WRSS1, and protective efficacy and immunogenecity in the guinea pig keratoconjunctivitis model. Infect. Immun. 66, 4572-4576   PUBMED
16 Herrington, D.A., L. Van DeVerg, S.B. Formal, T.L. Hale, B.D. Tall, S.J. Cryz, E.C. Tramont, and M.M. Levine. 1990. Studies in volunteers to evaluate candidate Shigella vaccine: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8, 353-357   DOI   ScienceOn
17 Khan, W.A., C. Seas, U. Dhar, M.A. Salam, and M.L. Bennish. 1997. Treatment of shigellosis: V. Comparison ofazithromycin and ciprofloxacin. A double-blind randomized controlled trial. Ann. Intern. Med. 126(9),697-703   DOI   PUBMED   ScienceOn
18 Kitasato, S. 1894. The bacillus of bubonic plague. Lancet. 2, 428-430
19 Koster, F., J. Levin, L. Walker, K.S. Tung, R.H. Gilman, M.M. Rahaman, M.M. Majid, S. Islam, and R.C. Williams. 1978. Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N. Eng. J. Med. 298, 927-933   DOI   ScienceOn
20 Kristjansson, M., B. Viner, and J.N. Maslow. 1994. Polymicrobial and recurrent bacteremia with in a patient with AIDS. Scand. J. Infect. Dis. 26, 411-416   DOI   ScienceOn
21 Levine, M.M., H.L. DuPont, S.B. Formal, R.B. Hornick, A. Takeuchi, E.J. Gangarosa, M.J. Snyder, and J.P. Libonati. 1973. Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J. Infect. Dis. 127, 261-270   DOI   PUBMED   ScienceOn
22 Mata, LJ., EJ. Gangarosa, A. Caceres, D.R. Perera, and M.L. Mejicanos. 1970. Epidemic Shiga bacillus dysentery in Central America. etiologic investigations in Guatemala, 1969. J. Infect. Dis. 122, 170-180   DOI   PUBMED   ScienceOn
23 Murphy, G, L. Bodhidatta, P Echeverria, S. Tansuphaswadikul, C. W. Hoge, S. Imlarp, and K. Tamura. 1993. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann. Intern. Med. 118, 582   DOI   PUBMED   ScienceOn
24 Nelson, J.D., H. Kusmiesz, and L.H. Jackson. 1976. Comparison of trimethoprim/ sulphamethoxazole and ampicillin therapy for shigellosis in ambulatory patients. J. Pediatr. 89, 491   DOI   PUBMED
25 Niyogi, S.K., U. Mitra, and P. Dutta. 2001. Changing pattern of serotypes and antimicrobial susceptibilities of Shigella species isolated from children in Calcutta, India. Jpn. J. Infect. Dis. 54, 121-122   PUBMED
26 Olsson-Liljequist, B. 1992. E-test as a routine MIC tool for reference work. Diagn. Microbiol. Infect. Dis. 15, 479-482   DOI   PUBMED   ScienceOn
27 Pal, S.C. 1984. Epidemic bacillary dysentery in West Bengal. Lancet. 1, 1462   PUBMED
28 Panhotra, B.R., B. Desai, and P.L. Sharma, 1985. Nalidixic acid resistant Shigella dysenteriae type 1. Lancet. 1, 763   PUBMED
29 Pozsgay, V., C. Chiayung, L. Pannel, J. Wolfe, J.B. Robbins, and R. Schneerson. 1999. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the a-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl. Acad. Sci. USA 96, 5194-5197
30 Robbins, J.B, C.Y. Chu, and R. Schneerson. 1992. Hypothesis for vaccine development: Protective immunity to enteric diseases caused by non-typhoidal Salmonella and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis. 15,346-361   DOI   PUBMED   ScienceOn
31 Sarkar, K., S. Ghosh, S.K. Niyogi, and S.K. Bhattacharya. 2003. Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolone. Lancet. 361, 785   PUBMED
32 Schuch, R. and A.T. Maurelli. 1999. The mxi-Spa type III secretory pathway of Shigella flexneri requires an outer membrane lipoprotein MxiM, for invasion translocation. Infect. Immun. 67, 1982-1991
33 Sen, D., P. Dutta, B.C. Deb, and S.C. Pal. 1988. Nalidixic acid resistant Shigella dysenteriae type 1 in Eastern India. Lancet. 2, 911   PUBMED
34 Shiga, K. 1906. Obsevation on the epidemiology of dysentery in Japan. Philippine J. of Sci. 1, 485-500
35 Sur, D., S.K. Niyogi, S. Sur, K.K. Datta, Y. Takeda, G.B. Nair, and S.K. Bhattacharya 2003. Multi-drug resistant Shigelaa dysenteriae type 1: Forerunners of a new epidemic strain in eastern India? Emerg. Inf. Dis. 9(3), 404-405   DOI
36 Todd, C. 1904. On a dysentery toxin and antitoxin. J. Hyg. 4, 480-494   DOI
37 World Health Organization. 1987. Manual for the investigation of acute enteric infections, programme for control of diarrhoeal diseases. Geneva CDD/83.3. Rev. 1
38 World Health Organization. 1997. New strategies for accelerating Shigella vaccine development. Weekly Epidemiol Record. 72, 73-80
39 Yavzori, M., D. Cohen, and N. Orr. 2002. Prevalence of the genes for shigella enterotoxin 1 and 2 among clinical isolates of shigella in Israel. Epidemiol. Infect. 128, 533-535   PUBMED
40 Bhattacharya, S.K., M.K. Bhattacharya, D. Dutta, S. Dutta, M. Deb, A Deb, K.P. Das, H. Koley, and G.B. Nair. 1997. Double blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr. 86, 319-320   DOI   ScienceOn
41 Finch, M., G. Rodey, D. Lawrence, and P. Blake. 1986. Epidemic Reiters syndrome following an outbreak of shigellosis. Eur. J. Epidemiol. 2, 26-30   DOI   ScienceOn
42 DuPont, H.L., C.D. Ericsson, J.J. Mathewson, E. Palazzini, M.W. DuPont, Z.D. Jiang, A. Mosavi, and F.J. de la Cabada. 1998. Rifaximin, a nonabsorbed antimicrobial, in the therapy of travelers diarrhoea. Digestion. 59, 708-714   DOI   ScienceOn
43 Salam, M.A., C. Seas, W.A. Khan, and M.L. Bennish. 1995. Treatment of shigellosis: IV cefixime is ineffective in shigellosis in adults. Ann. Intern. Med. 123(7), 505-508   DOI   PUBMED   ScienceOn
44 Shears, P. 1996. Shigella infection. Ann. Trop. Med. Parasitol. 90, 105-114   PUBMED
45 Sieper, J., J. Braun, P. Wu, R. Hauer, and S. Laitko. 1993. The possible role of Shigella in sporadic enteric reactive arthritis. Br. J. Rheumatol. 32, 582-585   DOI
46 Bose, R., J.N. Nashipuri, P.K. Sen, P. Dutta, S.K. Bhattacharya, D. Dutta, D. Sen, and M.K. Bhattacharya. 1984. Epidemic of dysentery in West Bengal: clinicians enigma. Lancet. 2, 1160   PUBMED
47 Butler, T., P. Speelman, I. Kabir, and J. Banwell. 1986. Colonic dysfunction during shigellosis. J. Infect. Dis. 154, 817-824   DOI   PUBMED   ScienceOn
48 DuPont, H.L., R.B. Hornick, A.T. Dawkins, M.J. Snyder, and S.B. Formal. 1969. The response of man to virulent Shigella flexneri 2a. J. Infect. Dis. 119, 296-299   DOI   PUBMED   ScienceOn
49 Shiga, K. 1936. The trend of prevention, therapy, and epidemiology of dysentery since the discovery of its causative organisms. N. Engl. J. Med. 215, 1205-1211   DOI
50 Angulo, F.J. and D.L. Swerdlow. 1995. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin. Inf. Dis. 21 Suppl. 1, S84-S93   DOI
51 McKee, K.T. Jr, T.M Shields, P.R. Jenkins, J.M Zenilman, and G. E. Glass. 2000. Application of a geographic information system to the tracing and control of an outbreak of shigellosis. Clin. Inf. Dis. 31, 728-733   DOI   ScienceOn
52 National Committee for Clinical Laboratory Standards. 1997. Performance standard antimicrobial disk susceptibility tests: approved standards. M2-A6, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa
53 Munshi, M.H., D.A. Sack, K. Halder, Z.U. Ahmed, M.M. Rahaman, and M.O. Murshed. 1987. Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet. 2,419-421   PUBMED
54 Nataro, J.P., J. Seriwatana, A. Fasano, D.R Maneval, L.D. Guers, F. Noriega, F. Dubovsky, M.M. Levine, and J.G Morris, Jr. 1995. Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect. Immun. 63, 4721-4728   PUBMED
55 Ross, S., G. Controno, and W. Khan. 1972. Resistance of shigellae to ampicillin and other antibiotic. J. Am. Med. Assoc. 221, 45   DOI   ScienceOn
56 Kotloff, K.L., J.P. Winickoff, B. Ivanoff, J.D. Clemens, D.L. Swerdlow, PJ. Sansonetti, G.K. Adak, and M.M. Levine. 1999. Global burden of Shigella infection:Implications for vaccine development and implementation of control strategies. Bull. WHO. 77, 651-666   PUBMED
57 Shiga, K. 1898. Ueber den Erreger der Dysenterie in Japan. Vorlaufige Mitteilung Zentralbal Bakteriol Microbiol Hyg. 23, 599-600
58 Flexner, S. 1900. On the etiology of tropical dysentery. Bull. Johns Hopkins Hosp. 11, 231-242
59 Salam, M.A. and M.L. Bennish. 1988. Therapy for shigellosis I randomized double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr. 113, 901-907   DOI   PUBMED
60 Acheson, D.W.K., A. Donohue-Rolfe, and G.T. Keusch.1991. The family of Shiga and Shiga-like toxins. p. 415-433. In J E Alouf and J H Freer (ed.), Sourcebook of Bacterial Protein Toxins. Academic Press, New York
61 Batchelor, B.I, J.N. Kimari, and R.J. Brindle. 1996. Microbiology of HIV associated bacteraemia and diarrhoea in adults from Nairobi, Kenya. Epidemiol. Infect. 117, 139-144   DOI   ScienceOn
62 Kruse, W. 1900. Ueberdie Ruhr als Volkskrankheit und ihrer erreger. Dtsch. Med. Wochenschr. 26, 637-639   DOI
63 Bhattacharya, S.K., K. Sarkar, G.B. Nair, A.S.G. Faruque, and D.A. Sack. 2003 A regional alert of multidrug-resistant Shigella dysenteriae type 1 in South Asia. The Lancet. Inf. Dis. 3, 751
64 Conradi, H. 1903. Uber losliche, durch aseptische auto lyse erhaltene giftstoffe von ruhrund typhus bazillen. Dtsch. Med. Wochenschr. 20, 26-28
65 Dorman, C.J. and M.E. Porter. 1998. The Shigella virulence regulatory cascade: a paradigm bacterial gene control mechanism. Mol. Microbiol. 29, 677-684   DOI   ScienceOn
66 Shiga, K. 1898. Ueber den Dysenterie bacillus (Bacillus dysenteriae), Zentralbl Bakteriol Parasitenkd Abt I Org. 24, 817-824
67 Struelens, M.J., D. Patte, I. Kabir, A. Salam, S.K. Nath, and T. Butler. 1985. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J. Infect. Dis. 152, 784-790   DOI   PUBMED   ScienceOn
68 Ashkenazi, S, J. Amir, Y. Waisman, A. Rachmel, B.Z. Garty, Z. Samra, I. varsano, and M.M. Nitzan. 1993. A randomized, double-blind study compairing cefixime and trimethoprim-sulphamethoxazole in the treatment of childhood shigellosis. J. Paediatr. 123, 817-821   DOI   ScienceOn
69 Coster, T.S., C.W. Hoge, L.L. Van DeVerg, AB. Hartman, E.V. Oaks, M.M. Venkatesan, D. Cohen, G Robin, AF. Thompson, P.J. Sansonetti, and T.L. Hale. 1999. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67, 3437-3443   PUBMED
70 Keusch, G. T. 1998. The rediscovery of Shiga toxin and its role in clinical disease. Jpn. J. Med. Sci. Biol. 51(Suppl. I), S5-S22
71 Trofa, A.F., H. Ueno-Olsen, R. Oiwa, and M. Yoshikawa. 1999. Dr. Kiyoshi Shiga: Discoverer of the dysentery bacillus. Clin. Infect. Dis. 29, 1303-1306   DOI   ScienceOn
72 Ackerman, B.H and E.A. Dello Buono. 1996. In vitro testing of anti-biotics. Pharmacotherapy 16, 201-221   PUBMED
73 Basualdo, W., and A. Arbo. 2003. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr: Infect. Dis. J. 22(4), 347-377
74 Noriega, F.R., Losonsky, G, Lauderbaugh, C., Liao, F.M. Wang, J.Y., and M.M. Levine. 1996. Engineered guaB-A virG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenecity, and potential efficacy as a mucosal vaccine. Infect. Immun. 64, 3055-3061   PUBMED
75 Rahaman, M.M., M.M. Khan, K.M.S. Aziz, M.S. Islam, and A.K. Kibriya. 1975. An outbreak of dysentery caused by Shigella dysenteriae type 1 on a coral island in the bay of Bengal. J. Infect. Dis. 132, 15-   DOI   PUBMED   ScienceOn
76 Salam, M.A. and M.L. Bennish. 1991. Antimicrobial therapy for shigellosis. Rev. Infect. Dis. 13(Suppl 4), S332-S341   DOI
77 Venkatesan, M., P.C. Fernandez, J.M. Buysee, S.B. Formal, and T.L. Hale. 1991. Virulence phenotype and genetic characteristics of the T32-1STRATI Shigella flexneri 2a vaccine strain. Vaccine 9, 358-363   DOI   ScienceOn
78 Bennish, M.L., and B.J. Wojtyniak. 1991. Mortality due to shigellosis: community and hospital data. Rev. Infect. Dis. 13(Suppl. 4), S245-251   DOI
79 Drusin, L.M. G Genvert, B. Topf-Olstein, and E. Levy-Zombeck. 1976. Shigellosis: Another sexually transmitted disease? Br. J. Vener. Dis. 52, 348-350   PUBMED
80 Way, S.S., A.C. Borczuk, R. Dominit, and M.B. Goldberg. 1998. An essential role for gamma interferon in inate resistance to Shigella flexneri infection. Infect. Immun. 66, 1342-1348   PUBMED
81 Guan, S. and N.K. Verma. 1998. Serotype conversion of a Shigella flexneri candidate vaccine strain via a novel site-specific chromosome-intigration system. FEMS Microbiol. Lett. 166, 79-87   DOI   ScienceOn
82 Hale, T.L. 1991. Genetic basis of virulence in Shigella species. Microbiol. Rev. 55, 206-224   PUBMED
83 Kotloff, K.L., F.R. Noriega, T. Samandari, M.B. Sztein, G.A. Losonsky, J.P. Nataro, W.D. Picking, E.M. Barry, and M.M. Levine. 2000. Shigellaflexneri 2a strain CVD 1207, with specific deletions in, virG, sen, set, and gua BA, is highly attenuated in humans. Infect. Immun. 68, 1034-1039   DOI   ScienceOn
84 Mounier, J., V. Laurent, A. Hall, P. Fort, M.E. Carlier, P.J. Sansonetti, and C. Egile. 1999. Rho family Gl'Pases control entry of Shigella flexneri into epithelial cells but not intracellular motility. J. Cell Sci. 112, 2069-2080   PUBMED
85 Way, S.S. and M.B. Goldberg. 1998. Clearence of Shigellaflexneri occurs through a nitric oxide independent mechanism. Infect. Immun. 66, 3012-3016   PUBMED
86 Bhattacharya, S.K., M.K. Bhattacharya, P. Dutta, D. Sen, R. Rasaily, A. Moitra, and S.C. Pal. 1991. Randomized clinical trial of norfloxacin for shigellosis. Am. J. Trop. Med. Hyg. 45, 683-687   PUBMED
87 Cohen, D., M.S. Green, C. Block, R. Slepon, and Y. Lerman. 1992. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide. J. Infect. Dis. 165, 785-787   DOI   PUBMED   ScienceOn
88 Obituary. The New York Times 1957 26 Jan. sec. 19,6
89 Ferreccio, C., V. Prado, A. Ojeda, M. Cayyazo, P. Abrego, L. Guers, and M.M. Levine. 1991.Epidemiologic patterns of acute diarrhoea and endemic Shigella infections in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol. 134, 614-627
90 Hong, M., M. Gleason, E.E. Wyckoff, and S.M. Payne. 1998. Identification of two Shigellaflexneri chromosomal loci involved in intercellular spreading. Infect. Immun. 66, 4700-4710   PUBMED
91 Varsano, I., T. Elditz-marcus, M. Nussinovch, and I. Elian. 1991. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J. Pediatr. 118, 627-632   DOI   PUBMED
92 Bhattacharya, S.K., and D. Sur. 2003. An evaluation of current shigellosis treatment. Expert Opin. Pharmacothe. 4(8), 1315-1320   DOI   ScienceOn
93 Mathan, V.I. and M.M. Mathan. 1991. Intestinal manifestations of invasive diarrhoeas and their diagnosis. Rev. Infect. Dis. 13 (Suppl 4), S311-313   DOI
94 Nhieu, G.T. and P.J. Sansonetti. 1999. Mechanism of Shigella entry into epithelial cells. Curr. Opin. Microbiol. 2, 51-56   DOI   PUBMED   ScienceOn
95 World Health Organization. 1995. The treatment of diarrhoea. A manual for physicians and other senior health workers. Geneva, Switzerland (WHO/CDR/95.3)
96 Finlay, B.B. and S.Falkow. 1997. Common themes in microbial pathogenecity revisited. Microbiol. Mol. Biol. Rev. 61, 136-169   PUBMED
97 Robbins, J.B, R. Schneerson, and S.C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious disease by inactivating the inoculum. J. Infect. Dis. 171, 1378-1398
98 Sansonetti, P.J. and C. Egile. 1998. Molecular bases of epithelial cell invasion by Shigella flexneri? Antonie Van Leeewenhoek. 74, 191-197   DOI   ScienceOn
99 Vargas, M., J. Gascon, M.T. Jimenez, De Anta., and J. Vila. 1999. Prevalence of Shigella enterotoxins 1 and 2 among Shigella strains isolated from patients with travelers diarrhoea. J. Clin. Microbiol. 37, 3608-3611   PUBMED
100 World Health Organization. 2001. Antimicrobial resistance in shigellosis, cholera and campylobacteriosis. WHO/CDS/CSR/ DRS/2001.8. World Health Organization, Geneva, Switzerland
101 Bergey's manual of Determinative Bacteriology. 3rd ed. Williams & Wilkins Co., Baltimore, Maryland 1930: 357-363
102 Gotuzzo, E., R.A. Oberhelman, C. Maguina, S.J. Berry, A. Yi, M. Guzman, R. Ruiz, R. Leon-Barua, and B. Sack. 1989. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulphamethoxazole for acute shigellosis in adults. Antimicrob. Agents Chemother. 33, 1101-1104   DOI   PUBMED   ScienceOn
103 Kotloff, K.L., J.P. Nataro, G.A. Losonsky, S.S. Wasserman, T.L. Hale, D.N. Taylor, J.C. Sadoff, and M.M. Levine. 1995. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine. 13, 1488-1494   DOI   ScienceOn
104 Levine, M.M. 1986. Antimicrobial therapy for infectious diarrhoea. Rev. Infect. Dis. 8, S207-S216   DOI
105 Levine, O.S. and M.M. Levine. 1991. House flies (Musca domestica) as mechanical vectors of shigellosis. Rev. Infect. Dis. 13, 688-696   DOI   PUBMED
106 Niyogi, S.K., M. Vargas, and J. Vila. 2004. Prevalence of the sat,set and sen genes among diverse serotypes of Shigella flexneri strains isolated from patients with acute diarrhoea. Clin. Microbiol. Infect. 10, 574-576   DOI   ScienceOn
107 Taylor, D., P. Echeverria, T. Pal, O. Sethabutr, S. Saiborisuth, S. Sricharmorn, B. Rowe, and J. Cross. 1986. The role of Shigella spp., enteroinvasive Escherichia coli and other enteropathogens as cause of childhood dysentery in Thailand. J. Infect. Dis. 153, 1132-1138   DOI   ScienceOn
108 Behring. E. and S. Kitasato. 1890. Ueber das Zustandkommen der Diphtherie-Immunitaet und der Tetanus-Immunitaet bei Thieren. Dtsch. Med. Wochenschr. 49,1-6
109 Formal, S.B., R.M. Maenza, S. Austin, and E.H. LaBrec. 1967. Failure of parenteral vaccine to protect monkeys against experimental shigellosis. Proc. Soc. Exp. Biol. Med. 125, 347-349
110 Levine, M.M. 1991. Shigellosis. In: Strickland G.T, HuntersTropical Medicine. 7th Edition. Philadelphia, WB Saunders Co., 340-344
111 Sack, R.B., M. Rahman, M. Yunus, and E.H. Khan. 1997 Antimicrobial resistance in organisms causing diarrhoeal disease. Clin. Infect. Dis. 24(suppl. 1), S102-105   DOI
112 McCormack, B.A., A.M. Siber, and A.T. Maurerelli. 1998. Requirement of the Shigella flexneri virulent plasmid in the ability to induce trafficking of neutrophils across polarized monolayers of the intestinal epithelium. Infect. Immun. 66, 4237-4243   PUBMED
113 Noriega, F.R., P.M. Liao, S.B. Formal, A. Fasano, and M.M. Levine. 1995. Prevalence of Shigella enterotoxin 1 among Shigella clinical isolates of diverse serotypes. J. Infect. Dis. 172, 1408-1410   DOI   PUBMED   ScienceOn
114 Sansonetti, P.J. and J. Arondel. 1989. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7, 443-450   DOI   ScienceOn
115 Shiga, K. and K. Kanwa. 1950. Tokyo: Nihon Iji Shimpo Shuppanbu